This page is part of the Logica COVID-19 FHIR Profile Library IG (v0.13.0: Drafts Ballot 1) based on FHIR R4. The current version which supercedes this version is 1.0.0. For a full list of available versions, see the Directory of published versions
Table of Contents
0 Table of Contents |
1 Home |
2 Logica Comparison to E ICR |
3 Patient Demographics and Vital Signs |
4 Case Reporting Info |
5 Exposure Info |
6 Signs Symptoms Diagnoses Comorbidities |
7 Lab Profiles |
8 Smoking Status Pregnancy Status |
9 Exposure Questionnaire |
10 COVID 19 Immunization |
11 Downloads |
12 History |
13 Artifacts Summary |
13.1 COVID 19 Exposure Core profile |
13.2 Coded Laboratory Observation Base |
13.3 Laboratory Observation Base |
13.4 Laboratory Observation Panel Base |
13.5 Quantitative Laboratory Observation Base |
13.6 UnderlyingConditionObservationParent |
13.7 COVID 19 Exposure Questionnaire |
13.8 COVID-19 gastrointestinal and hepatic underlying condition |
13.9 COVID-19 hemoglobinopathy underlying condition |
13.10 COVID-19 ICD 10 Diagnosis |
13.11 COVID-19 immune underlying condition |
13.12 COVID-19 Immunization |
13.13 COVID 19 Vaccine Manufacturer |
13.14 COVID-19 renal underlying condition |
13.15 COVID-19 respiratory underlying condition |
13.16 COVID-19 SNOMED Diagnosis |
13.17 COVID 19 Symptoms Absent |
13.18 COVID 19 Symptoms Present |
13.19 COVID-19 uncategorized underlying condition |
13.20 COVID-19 cardiovascular underlying condition |
13.21 COVID-19 Underlying Medical Condition observation |
13.22 COVID-19 immunocompromised underlying condition |
13.23 COVID-19 General Underlying Conditions Absent |
13.24 COVID-19 General Underlying Conditions Present |
13.25 COVID-19 metabolic underlying condition |
13.26 COVID-19 neurologic underlying condition |
13.27 Case-Patient Report Identifying Information |
13.28 Exposure Type |
13.29 Influenza virus A and B RNA and SARS-CoV-2 (COVID-19) N gene panel - Respiratory specimen by NAA with probe detection |
13.30 Influenza virus A and B and SARS-CoV-2 (COVID-19) identified in Respiratory specimen by NAA with probe detection |
13.31 Influenza virus A and B and SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory specimen by NAA with probe detection |
13.32 Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory specimen by NAA with probe detection |
13.33 Influenza virus A and B and SARS-CoV+SARS-CoV-2 (COVID-19) Ag panel - Upper respiratory specimen by Rapid immunoassay |
13.34 Influenza virus A RNA [Presence] in Respiratory specimen by NAA with probe detection |
13.35 Influenza virus B RNA [Presence] in Respiratory specimen by NAA with probe detection |
13.36 Gamma interferon background [Units/volume] in Blood by Immunoassay |
13.37 Gestational Age at Onset of Illness |
13.38 Human coronavirus 229E+HKU1+OC43+NL63 RNA [Presence] in Nasopharynx by NAA with non-probe detection |
13.39 Human coronavirus 229E RNA [Presence] in Nasopharynx by NAA with non-probe detection |
13.40 Human coronavirus HKU1 RNA [Presence] in Nasopharynx by NAA with non-probe detection |
13.41 Human coronavirus NL63 RNA [Presence] in Nasopharynx by NAA with non-probe detection |
13.42 Human coronavirus OC43 RNA [Presence] in Nasopharynx by NAA with non-probe detection |
13.43 Influenza virus A Ag [Presence] in Nasopharynx by Rapid immunoassay |
13.44 Influenza virus B Ag [Presence] in Nasopharynx by Rapid immunoassay |
13.45 Known Exposure |
13.46 Mitogen stimulated gamma interferon [Units/volume] corrected for background in Blood |
13.47 Mitogen stimulated gamma interferon [Units/volume] in Blood |
13.48 Pregnancy Status |
13.49 Respiratory syncytial virus RNA [Presence] in Respiratory specimen by NAA with probe detection |
13.50 SARS-CoV-2 (COVID19) IgG Ab [Presence] in DBS by Immunoassay |
13.51 SARS-CoV-2 (COVID19) Ab [Units/volume] in Serum or Plasma by Immunoassay |
13.52 SARS-CoV-2 (COVID19) IgA Ab [Presence] in Serum, Plasma, or Blood by Rapid imunoassay |
13.53 SARS-CoV-2 (COVID19) IgA + IgM [Presence] in Serum or Plasma by Immunoassay |
13.54 SARS-CoV-2 (COVID19) Ab [Presence] in Serum or Plasma by Immunoassay |
13.55 SARS-CoV-2 (COVID19) Ag [Presence] in Respiratory specimen by Rapid immunoassay |
13.56 SARS-CoV-2 (COVID19) E gene [Presence] in Respiratory specimen by NAA with probe detection |
13.57 SARS-CoV-2 (COVID19) E gene [Presence] in Serum or Plasma by NAA with probe detection |
13.58 SARS-CoV-2 (COVID19) N gene [Presence] in Nasopharynx by NAA with probe detection |
13.59 SARS-CoV-2 (COVID19) N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N1 |
13.60 SARS-CoV-2 (COVID19) N gene [Presence] in Respiratory specimen by Nucleaic acid amplification using CDC primer-probe set N2 |
13.61 SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by Nucleic acid amplification using CDC primer-probe set N1 |
13.62 SARS-CoV-2 (COVID19) N gene [Presence] in Serum or Plasma by NAA with probe detection |
13.63 SARS-CoV-2 (COVID19) N gene [Presence] in Unspecified specimen by Nucleic acid amplification using primer-probe set N1 |
13.64 SARS-CoV-2 (COVID19) N gene [Presence] in Unspecified specimen by Nucleic acid amplification using primer-probe set N2 |
13.65 SARS-CoV-2 (COVID19) N gene [Cycle Threshold #] in Unspecified specimen by Nucleic acid amplification using primer-probe set N1 |
13.66 SARS-CoV-2 (COVID19) N gene [Cycle Threshold #] in Unspecified specimen by Nucleic acid amplification using primer-probe set N2 |
13.67 SARS-CoV-2 (COVID19) ORF1ab region [Presence] in Respiratory specimen by NAA with probe detection |
13.68 SARS-CoV-2 (COVID19) [Presence] in Unspecified specimen by Organism specific culture |
13.69 SARS-CoV-2 (COVID19) RNA [Cycle Threshold#] in Respiratory specimen by NAA with probe detection |
13.70 SARS-CoV-2 (COVID19) RNA [Log#/volume] (viral load) in Unspecified specimen by NAA with probe detection |
13.71 SARS-Cov-2 (COVID19) RNA panel - Unspecified specimen by NAA with probe detection |
13.72 Sars-CoV-2 (COVID19) RNA [Presence] in Nasopharynx by NAA with probe detection |
13.73 SARS-CoV-2 (COVID19) RNA [Presence] in Saliva (oral fluid) by NAA with probe |
13.74 SARS-CoV-2 (COVID19) RNA [Presence] in Saliva (oral fluid) by Sequencing |
13.75 SARS-CoV-2 (COVID19) RNA [Cycle Threshold#] in Unspecified specimen by NAA with probe detection |
13.76 SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Lower respiratory specimen by NAA with probe detection |
13.77 SARS-CoV-2 (COVID19) S gene [Presence] in Serum or Plasma by NAA with probe detection |
13.78 SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory specimen by NAA with probe detection |
13.79 SARS-CoV-2 (COVID-19) specific TCRB gene rearrangements [Presence] in Blood by Sequencing |
13.80 SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Presence] in Serum or Plasma by Immunoassay |
13.81 SARS CoV-2 stimulated gamma interferon release by T-cells [Units/volume] corrected for background in Blood |
13.82 SARS CoV-2 stimulated gamma interferon release by T-cells [Units/volume] in Blood |
13.83 SARS-coV-2 (COVID19) whole genome [Nucleiotide sequence] in Isolate by Sequencing |
13.84 SARS-CoV + SARS-Cov-2 (COVID19) Ag [Presence] in Respiratory specimen by Rapid immunoassay |
13.85 SARS-like coronavirus N gene [Presence] in Unspecified specimen by NAA with probe detection |
13.86 SARS-like coronavirus N gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection |
13.87 SARS-related coronavirus RNA [Presence] in Respiratory specimen by NAA with probe detection |
13.88 SARS-CoV-2 (COVID19) IgA Ab [Units/volume] in Serum or Plasma by Immunoassay |
13.89 SARS-CoV-2 (COVID19) IgA Ab [Presence] in Serum or Plasma by Immunoassay |
13.90 SARS-CoV-2 (COVID-19) IgA Ab [Titer] in Serum or Plasma by Immunofluorescence |
13.91 SARS-CoV-2 (COVID19) IgG Ab [Units/volume] in Serum or Plasma by Immunoassay |
13.92 SARS-CoV-2 (COVID-19) IgG+IgM Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay |
13.93 SARS-CoV-2 (COVID19) IgG+IgM Ab [Presence] in Serum or Plasma by Immunoassay |
13.94 SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay |
13.95 SARS-CoV-2 (COVID19) IgG Ab [Presence] in Serum or Plasma by Immunoassay |
13.96 SARS-CoV-2 (COVID-19) IgG Ab [Titer] in Serum or Plasma by Immunofluorescence |
13.97 SARS-CoV-2 (COVID19) IgG and IgM panel - Serum or Plasma Qualitative by Rapid immunoassay |
13.98 SARS-CoV-2 (COVID19) IgG and IgM panel - Serum or Plasma by Immunoassay |
13.99 SARS-CoV-2 (COVID19) IgM Ab [Units/volume] in Serum or Plasma by Immunoassay |
13.100 SARS-CoV-2 (COVID-19) IgM Ab [Presence] in DBS by Immunoassay |
13.101 SARS-CoV-2 (COVID19) IgM Ab [Presence] in Serum or Plasma by Immunoassay |
13.102 SARS-CoV-2 (COVID19) IgM Ab [Presence] in Serum or Plasma by Rapid immunoassay |
13.103 SARS-CoV-2 (COVID-19) IgM Ab [Titer] in Serum or Plasma by Immunofluorescence |
13.104 SARS-CoV-2 (COVID19) Ab [Interpretation] in Serum or Plasma |
13.105 SARS-CoV-2 (COVID-19) neutralizing antibody [Presence] in Serum by pVNT |
13.106 SARS-CoV-2 (COVID-19) neutralizing antibody [Titer] in Serum by pVNT |
13.107 SARS-CoV-2 (COVID-19) Ab [Presence] in DBS by Immunoassay |
13.108 SARS-CoV-2 (COVID-19) Ab panel - DBS by Immunoassay |
13.109 SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay |
13.110 SARS-CoV-2 (COVID19) E gene [Presence] in Unspecified specimen by NAA with probe detection |
13.111 SARS-CoV-2 (COVID19) E gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection |
13.112 SARS-CoV-2 (COVID-19) N gene [Log #/volume] (viral load) in Respiratory specimen by NAA with probe detection |
13.113 SARS-CoV-2 (COVID-19) N gene [#/volume] (viral load) in Respiratory specimen by NAA with probe detection |
13.114 SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with probe detection |
13.115 SARS-CoV-2 (COVID19) N gene [Presence] in Respiratory specimen by NAA with probe detection |
13.116 SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by NAA with probe detection |
13.117 SARS-CoV-2 (COVID19) N gene [Presence] in Unspecified specimen by NAA with probe detection |
13.118 SARS-CoV-2 (COVID19) N gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection |
13.119 SARS-CoV-2 (COVID19) ORF1ab region [Cycle Threshold #] in Unspecified specimen by NAA with probe detection |
13.120 SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Saliva (oral fluid) by NAA with probe detection |
13.121 SARS-CoV-2 (COVID19) ORF1ab region [Presence] in Unspecified specimen by NAA with probe detection |
13.122 SARS-CoV-2 (COVID19) ORF1ab region [Cycle Threshold #] in Respiratory specimen by NAA with probe detection |
13.123 SARS-CoV-2 (COVID19) RNA panel - Respiratory specimen by NAA with probe detection |
13.124 SARS-CoV-2 (COVID-19) RNA [Presence] in Nose by NAA with probe detection |
13.125 SARS-CoV-2 (COVID19) RNA [Presence] in Nasopharynx by NAA with non-probe detection |
13.126 SARS-CoV-2 (COVID19) RNA [Presence] in Respiratory specimen by NAA with probe detection |
13.127 SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by NAA with non-probe detection |
13.128 SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by Sequencing |
13.129 SARS-CoV-2 (COVID19) RNA [Presence] in Serum or Plasma by NAA with probe detection |
13.130 SARS-CoV-2 (COVID19) RNA [Presence] in Unspecified specimen by NAA with probe detection |
13.131 SARS-CoV-2 (COVID-19) RNA panel - Saliva (oral fluid) by NAA with probe detection |
13.132 SARS-CoV-2 (COVID19) RdRp gene [Presence] in Respiratory specimen by NAA with probe detection |
13.133 SARS-CoV-2 (COVID19) RdRp gene [Presence] in Unspecified specimen by NAA with probe detection |
13.134 SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Upper respiratory specimen by NAA with probe detection |
13.135 SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Saliva (oral fluid) by NAA with probe detection |
13.136 SARS-CoV-2 (COVID19) RdRp gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection |
13.137 SARS-CoV-2 (COVID19) RdRp gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection |
13.138 SARS-CoV-2 (COVID19) S gene [Presence] in Respiratory specimen by NAA with probe detection |
13.139 SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory specimen by Sequencing |
13.140 SARS-CoV-2 (COVID19) S gene [Presence] in Unspecified specimen by NAA with probe detection |
13.141 SARS-CoV-2 (COVID19) S gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection |
13.142 SARS-CoV-2 (COVID19) S gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection |
13.143 SARS CoV-2 stimulated gamma interferon [Presence] in Blood |
13.144 SARS CoV-2 stimulated gamma interferon panel - Blood |
13.145 SARS-related coronavirus+MERS coronavirus RNA [Presence] in Respiratory specimen by NAA with probe detection |
13.146 SARS-related coronavirus E gene [Presence] in Saliva (oral fluid) by NAA with probe detection |
13.147 SARS-related coronavirus RNA [Presence] in Unspecified specimen by NAA with probe detection |
13.148 SARS-related coronavirus E gene [Presence] in Lower respiratory specimen by NAA with probe detection |
13.149 SARS-related coronavirus E gene [Presence] in Upper respiratory specimen by NAA with probe detection |
13.150 Travel History |
13.151 COVID-19 Underlying Condition Code |
13.152 COVID-19 Underlying Condition Reference |
13.153 Certainty of Absence |
13.154 Certainty of Presence |
13.155 Procedure Code |
13.156 Reporting Priority |
13.157 Antibody Not Detected, Past/Recent Infection LOINC answer value set. |
13.158 COVID-19 cardiovascular underlying condition reference set |
13.159 COVID-19 Disease Severity Value Set |
13.160 COVID-19 ICD 10 Diagnosis Value Set |
13.161 COVID-19 SNOMED CT Diagnosis Value Set |
13.162 COVID-19 Signs and Symptoms Severity Value Set |
13.163 COVID-19 Signs and Symptoms Value Set |
13.164 COVID-19 uncategorized underlying condition reference set |
13.165 COVID-19 gastrointestinal or hepatic underlying condition reference set |
13.166 COVID-19 hemoglobinopathy underlying condition reference set |
13.167 COVID-19 immune underlying condition reference set |
13.168 COVID-19 immunocompromised underlying condition reference set |
13.169 COVID-19 Underlying Medical Condition Value Set |
13.170 COVID-19 metabolic underlying condition reference set |
13.171 COVID-19 neurologic underlying condition reference set |
13.172 COVID-19 renal underlying condition reference set |
13.173 COVID-19 respiratory underlying condition reference set |
13.174 COVID 19 CVX Code System Vaccine Codes |
13.175 Certainty of Absence Value Set |
13.176 Certainty of Presence Value Set |
13.177 Close Contact Setting Value Set |
13.178 Detected, Not Detected, Inconclusive Value Set |
13.179 Detected, Not-detected, Equivocal, Invalid value set |
13.180 Detected, Not-detected Value Set |
13.181 Detected, Not-detected, Inconclusive, Invalid value set |
13.182 Detected, Not-detected value set |
13.183 Influenza A, Influenza B, SARS CoV 2, and SARS CoV value set |
13.184 Influenza A, Influenza B, and SARS CoV2 value set |
13.185 Healthcare Occupation Value Set |
13.186 ISO Code System 3166 country codes |
13.187 ISO Code System 3166 state/province codes. |
13.188 Known Exposure LOINC Answer Value Set |
13.189 Positive/Negative Value Set |
13.190 COVID19 Positive, Negative, Indeterminate value set |
13.191 COVID19 Positive Negative Invalid value set |
13.192 COVID19 Positive Negative Suspected Invalid value set |
13.193 Positive, Negative value set |
13.194 Pregnancy Status Value Set |
13.195 Present, Absent, Unknown Value Set |
13.196 Reactive - Non-reactive value set |
13.197 COVID19 Reactive, Non-reactive, Invalid value set |
13.198 COVID19 Reactive Non-reactive value set |
13.199 Reporting Priorities Value Set |
13.200 Smoking Status Value Set |
13.201 State Codes Value Set |
13.202 Yes/No Value Set |
13.203 COVID19 Undefined Lab Values code system |
13.204 COVID19 Underlying Condition Category Code System |